The importance of a thorough medical and pharmacological history before dental implant placement

Australian Dental Journal

Volumn 57, Issue 3, 2012, Pages 388-392

  Zadik, Y ^a,b   Abu Tair, J ^b   Yarom, N ^c,d   Zaharia, B ^b   Elad, S ^e  

^a Medical Corps ^*  (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

^e UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Alendronate; bisphosphonate related osteonecrosis of the jaws; education; oral medicine; oral surgery; review of systems

Indexed keywords

ALENDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

AGED; ANAMNESIS; ARTICLE; CASE REPORT; DRUG CONTRAINDICATION; FEMALE; HUMAN; JAW OSTEONECROSIS; METHODOLOGY; ORAL SURGERY; OSTEOPOROSIS; RISK ASSESSMENT; TOOTH IMPLANT;

AGED; ALENDRONATE; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; DENTAL IMPLANTS; FEMALE; HUMANS; MEDICAL HISTORY TAKING; ORAL SURGICAL PROCEDURES; OSTEOPOROSIS; RISK ASSESSMENT;

EID: 84865801442     PISSN: 00450421     EISSN: 18347819     Source Type: Journal    
DOI: 10.1111/j.1834-7819.2012.01717.x     Document Type: Article

References (35)

1. Borromeo GL, Tsao CE, Darby IB, Ebeling PR,. A review of the clinical implications of bisphosphonates in dentistry. Aust Dent J 2011; 56: 2-9.
2. Mavrokokki T, Cheng A, Stein B, Goss A,. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007; 65: 415-423. (Pubitemid 46343586)
3. Ficarra G, Beninati F, Rubino I, et al., Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol 2005; 32: 1123-1128. (Pubitemid 41499467)
4. Levin L, Laviv A, Schwartz-Arad D,. Denture-related osteonecrosis of the maxilla associated with oral bisphosphonate treatment. J Am Dent Assoc 2007; 138: 1218-1220.
5. Yarom N, Yahalom R, Shoshani Y, Hamed W, Regev E, Elad S,. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 2007; 18: 1363-1370. (Pubitemid 47389465)
6. Cheng A, Daly CG, Logan RM, Stein B, Goss AN,. Alveolar bone and the bisphosphonates. Aust Dent J 2009; 54 (Suppl 1): S51-61.
7. Goss A, Bartold PM, Sambrook P, Hawker P,. The nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in dental implant patients: a South Australian case series. J Oral Maxillofac Surg 2010; 68: 337-343.
8. Sedghizadeh PP, Stanley K, Caligiuri M, Hofkes S, Lowry B, Shuler CF,. Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry. J Am Dent Assoc 2009; 140: 61-66.
9. Lo JC, O'Ryan FS, Gordon NP, et al., Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 2010; 68: 243-253.
10. Cooper C,. Osteoporosis: disease severity and consequent fracture management. Osteoporos Int 2010; 21: S425-429.
11. Ruggiero SL, Dodson TB, Assael LA, et al., American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 2009; 67: S2-12.
12. Lazarovici TS, Yahalom R, Taicher S, Schwartz-Arad D, Peleg O, Yarom N,. Bisphosphonate-related osteonecrosis of the jaw associated with dental implants. J Oral Maxillofac Surg 2010; 68: 790-796.
13. Zadik Y, Benoliel R, Fleissig Y, Casap N,. Painful trigeminal neuropathy induced by oral-bisphosphonate related osteonecrosis of jaw: a new etiology for the numb-chin syndrome. Quintessence Int 2012; 43: 97-104.
14. Miksad RA, Lai KC, Dodson TB, et al., Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw. Oncologist 2011; 16: 121-132.
15. Mehanna P, Goddard R,. Bisphosphonate associated osteonecrosis: an unusual case. Aust Dent J 2010; 55: 311-313.
16. Sambrook P, Olver I, Goss A,. Bisphosphonates and osteonecrosis of the jaw. Aust Fam Physician 2006; 35: 801-803.
17. Kunchur R, Goss AN,. The oral health status of patients on oral bisphosphonates for osteoporosis. Aust Dent J 2008; 53: 354-357.
18. Liddelow G, Klineberg I,. Patient-related risk factors for implant therapy. A critique of pertinent literature. Aust Dent J 2011; 56: 417-426.
19. Marx RE, Cillo JE Jr, Ulloa JJ,. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007; 65: 2397-2410. (Pubitemid 350100982)
20. Lazarovici TS, Mesilaty-Gross S, Vered I, et al., Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates. J Oral Maxillofac Surg 2010; 68: 2241-2247.
21. Regev E, Lustmann J, Nashef R,. Atraumatic teeth extraction in bisphosphonate-treated patients. J Oral Maxillofac Surg 2008; 66: 1157-1161. (Pubitemid 351671952)
22. Lodi G, Sardella A, Salis A, Demarosi F, Tarozzi M, Carrassi A,. Tooth extraction in patients taking intravenous bisphosphonates: a preventive protocol and case series. J Oral Maxillofac Surg 2010; 68: 107-110.
23. Ferlito S, Puzzo S, Liardo C,. Preventive protocol for tooth extractions in patients treated with zoledronate: a case series. J Oral Maxillofac Surg 2011; 69: e1-4.
24. Little JW, Falace DA, Miller CS, Rhodus NL,. Physical evaluation and risk assessment. In: Dental management of the medically compromised patient. 7th edn. St. Louis: Mosby Elsevier, 2008: 2-16.
25. Scully C, Cawson RA,. Medical history and assessment. In: Medical problems in dentistry. 5th edn. Edinburgh: Elsevier, 2005: 1-14.
26. Fleissig Y, Regev E, Lehman H,. Sunitinib related osteonecrosis of jaw: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2012; 113: e1-3.
27. Brennan MT, Woo SB, Lockhart PB,. Dental treatment planning and management in the patient who has cancer. Dent Clin North Am 2008; 52: 19-37.
28. Wessel JH, Dodson TB, Zavras AI,. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg 2008; 66: 625-631. (Pubitemid 351381804)
29. Vahtsevanos K, Kyrgidis A, Verrou E, et al., Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 2009; 27: 5356-5362.
30. Yarom N, Elad S, Madrid C, Migliorati CA,. Osteonecrosis of the jaws induced by drugs other than bisphosphonates-a call to update terminology in light of new data. Oral Oncol 2010; 46: e1.
31. de Jong KJ, Abraham-Inpijn L, Vinckier F, Declerck D,. The validity of a medical risk-related history for dental patients in Belgium. Int Dent J 1997; 47: 16-20. (Pubitemid 127521706)
32. Abraham-Inpijn L, Russell G, Abraham DA, et al., A patient-administered Medical Risk Related History questionnaire (EMRRH) for use in 10 European countries (multicenter trial). Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 105: 597-605.
33. Misch CE, Resnik RR,. Medical evaluation of the dental implant patient. In:, Misch CE, ed. Contemporary implant dentistry. 3rd edn. St. Louis: Mosby Elsevier, 2008: 421-466.
34. Ruggiero SL, Woo SB,. Bisphosphonate-related osteonecrosis of the jaws. Dent Clin North Am 2008; 52: 111-128.
35. Cheng A, Mavrokokki A, Carter G, et al., The dental implications of bisphosphonates and bone disease. Aust Dent J 2005; 50 (4 Suppl 2): S4-13. (Pubitemid 43074661)